{"disease":{"id":"plasma-cell-disorders","name":"plasma cell disorders"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06286215","title":"Registry of Patients With Plasma Cell Disorders","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT06252948","title":"Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06271252","title":"A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"OriCell Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT05280275","title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Hellenic Society of Hematology","has_results":false},{"nct_id":"NCT05573802","title":"A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Hellenic Society of Hematology","has_results":false},{"nct_id":"NCT04309084","title":"Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT07115667","title":"Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}